Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Goldline Pharmaceutical Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹43
Per ShareLot Size
3000 Shares
Minimum Investment
₹1,29,000
Issue Size
₹11.61 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.13%
QIB Quota
49.65%
NII Quota
15.22%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
79.7%
Promoter Holding (Post-Issue)
57.3%
Issue Type
Book Building - SME
ISIN
INE1CLW01015
We are engaged in the business of marketing pharmaceutical products under the brand name "Goldline." Our product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed under the "Goldline" brand are not manufactured by our Company. Instead, we enter into contractual arrangements with third-party manufacturers, who produce the products based on our market research, demand analysis, and specifications. These contractual arrangements ensure that all products meet the requisite quality standards and regulatory norms.
The Indian pharmaceutical industry is the world's 3rd largest by volume of production and plays a significant role globally. India is a global leader in the supply of DPT, BCG, and Measles vaccines and one of the largest suppliers of low-cost vaccines in the world. Indian manufacturers account for 60 percent of the vaccine supplies to UNICEF, contributing 40 to 70 percent of the WHO demand for Diphtheria, Tetanus and Pertussis (DPT) and Bacillus Calmette-Guérin (BCG) vaccines, and 90 percent of the WHO demand for the measles vaccine. India has the highest number of United States Food and Drug Administration (USFDA) compliant pharma plants outside of the USA. There are 500 API manufacturers contributing about 8% to the global API Industry. India is the largest supplier of generic medicines, with a 20% share in the global supply by manufacturing 60,000 different generic brands across 60 therapeutic categories.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public issue of 27,00,000 equity shares of face value of Rs. 10/- each ("Equity Shares") of Goldline Pharmaceutical Limited ("Issuer" or "The" "company") at an issue price of Rs. 43 per equity share (including a share premium of Rs. 33 per equity share) for cash, aggregating to Rs. 11.61 Crores ("Public Issue") out of which 1,38,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 43 per equity share for cash, aggregating Rs. 0.59 Crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 25,62,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 43 per equity share for cash, aggregating up to Rs. 11.02 Crores is hereinafter referred to as the "Net Issue". The public issue and net issue will constitute 28.13% and 26.69% respectively of the post-issue paid-up equity share capital of the company. Price Band is Rs. 43 per equity share of face value of Rs. 10/- each. The floor price is 4.3 times of the face value. Bids can be made for a minimum of Two lot and in multiples of 3,000 equity shares thereafter.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Goldline Pharmaceutical Limited (the "Issuer" or our "Company") was incorporated on August 02, 2004 as `Goldline Pharmaceutical Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 02, 2004 issued by the Registrar of Companies, Maharashtra at Mumbai. Further, our Company was converted into a public limited company pursuant to a resolution passed by the Shareholders in an extraordinary general meeting held on July 18, 2013 and consequently the name of our Company was changed to `Goldline Pharmaceutical Limited' and a fresh certificate of incorporation dated September 23, 2013 was issued by the Registrar of Companies, Maharashtra at Mumbai. The corporate identity number of our Company is U51397MH2004PLC147806.
Wholesaler and Retailer
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.